3008:TWSELARGAN Precision Co., Ltd. Analysis
Data as of 2026-03-11 - not real-time
CN¥63.66
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical outlook appears strong: the stock trades at CNY 63.66, comfortably above its 20‑day SMA (≈57), 50‑day SMA (≈53) and 200‑day SMA (≈48), and the MACD line sits bullishly above its signal (2.76 vs 1.98) with a positive histogram. Momentum is supported by an RSI of ~61 and a clear bullish trend direction, while volume is on an increasing trajectory.
Fundamental backdrop is weak: revenue is contracting (‑2.7%), margins are deeply negative (gross ‑4.1%, operating ‑49.7%, profit ‑45.9%), EPS is –0.86 and the company carries a high price‑to‑book of ~11.5 versus a DCF‑derived fair value of only CNY 2.66. No dividend is paid, cash flow is modest, and the stock exhibits extreme 30‑day volatility (~82%) despite a low beta (~0.37). Combined with heightened regulatory scrutiny on Chinese tech firms, the valuation looks significantly stretched.
Fundamental backdrop is weak: revenue is contracting (‑2.7%), margins are deeply negative (gross ‑4.1%, operating ‑49.7%, profit ‑45.9%), EPS is –0.86 and the company carries a high price‑to‑book of ~11.5 versus a DCF‑derived fair value of only CNY 2.66. No dividend is paid, cash flow is modest, and the stock exhibits extreme 30‑day volatility (~82%) despite a low beta (~0.37). Combined with heightened regulatory scrutiny on Chinese tech firms, the valuation looks significantly stretched.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bullish technical indicators (price above SMAs, MACD bullish)
- Increasing volume supporting short‑term momentum
- Persistently negative earnings and high valuation
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- Fundamentals remain weak with negative margins and EPS
- Market price far exceeds DCF fair value
- Regulatory environment for Chinese tech remains uncertain
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Structural overvaluation (PB >11, price vs fair value gap)
- No dividend and limited cash generation
- High volatility and ongoing sector/regulatory risks
Key Metrics & Analysis
Financial Health
Revenue Growth-2.70%
Profit Margin-45.87%
ROE-15.01%
ROA-5.63%
Debt/Equity2.25
P/B Ratio11.5
Op. Cash FlowCN¥2.9M
Free Cash FlowCN¥19.7M
Industry P/E36.8
Technical Analysis
TrendBullish
RSI61.5
SupportCN¥48.00
ResistanceCN¥66.72
MA 20CN¥57.00
MA 50CN¥53.24
MA 200CN¥47.92
MACDBullish
VolumeIncreasing
Fear & Greed Index76.91
Valuation
Fair ValueCN¥2.66
GradeOvervalued
TypeValue
Risk Assessment
Beta0.37
Volatility81.58%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.